Can I Give Myself Allergy Shots? How At-Home SCIT Works Safely

It can be — for eligible patients with the right safeguards. The real concern is the systemic reaction risk: allergy shots carry a 0.1-0.2% rate of systemic reactions per injection — including anaphylaxis — which can progress within minutes, and AAAAI surveillance shows historical SCIT fatalities occurred almost exclusively without trained supervision or with delayed epinephrine. Curex's at-home SCIT engineers out exactly those two risk factors: a prescribed epinephrine auto-injector is confirmed on hand before the first dose, a board-certified allergist trains the patient on injection technique and emergency response, the first injection and every dose change are supervised live over Zoom, and the serum is sterile-compounded to USP <797> standards. Patients who are not eligible — uncontrolled asthma, prior severe reactions — are identified during candidacy review and referred to in-person care.

An allergist approves at-home allergy shots through a structured candidacy review, not a casual sign-off. Curex's board-certified allergists confirm IgE-mediated sensitization, rule out contraindications (uncontrolled asthma, prior Grade 3+ systemic reactions, beta-blocker conflicts), and confirm the patient can store and correctly use a prescribed epinephrine auto-injector before any home dose. The safeguards then travel with the patient: the first injection and every dose change are supervised live over Zoom, dose escalation follows the same gradual protocol used in clinics, and the care team is reachable throughout. Patients who do not meet candidacy criteria are identified up front and referred to in-person care — eligibility is honest, not universal.

Unsupervised self-injection means giving yourself the same subcutaneous shots as the clinic but with no safety net — the same 0.1-0.2% systemic reaction risk per injection and no one trained or no epinephrine plan nearby. Supervised at-home SCIT keeps the identical immunotherapy and adds back the safety net remotely: with Curex, a board-certified allergist supervises your first injection and every dose change live over Zoom, a prescribed epinephrine auto-injector is confirmed on hand before you start, and the serum is sterile-compounded to USP <797> standards. Sublingual drops (SLIT) are a different modality — placed under the tongue, with a lower systemic reaction risk and no confirmed fatalities (Canonica et al., WAO Journal, 2014) — but they are a separate treatment, not a substitute for the shot itself when SCIT is the right choice.

Sublingual immunotherapy (SLIT) has demonstrated significant clinical efficacy in randomized controlled trials, particularly for dust mite, grass pollen, and ragweed allergens. Durham et al. (Allergy, 2012) reviewed the SLIT evidence base and found consistent improvement in symptom scores and medication use. Head-to-head comparisons suggest SCIT may produce somewhat larger symptom reduction for some allergens, particularly complex multi-allergen combinations, while SLIT shows comparable or near-comparable efficacy for key single allergens with a much better safety profile. The choice between SCIT and SLIT often turns on access, lifestyle, risk tolerance, and adherence — SLIT's home-administration convenience tends to support better long-term adherence, which affects real-world outcomes significantly.

If anaphylaxis occurs, the outcome depends critically on whether epinephrine is immediately available and whether help can respond fast — which is exactly why Curex's at-home SCIT requires a prescribed epinephrine auto-injector confirmed on hand before the first dose and trains patients on emergency response. Anaphylaxis can progress from throat tingling to loss of consciousness within 5-10 minutes without treatment. If a reaction occurs: use the epinephrine auto-injector immediately (inject into the outer thigh), call 911, lie flat with legs elevated unless breathing is difficult, and do not wait to see if symptoms improve before calling for help. A second dose may be needed if symptoms return before emergency services arrive. Curex's model — prescribed epinephrine on hand, allergist training, and Zoom-supervised first and changed doses — is built specifically so this scenario is managed, not left to chance.

Children should not self-administer allergy shots under any circumstances — the developmental capacity for reliable self-injection technique, self-assessment of reaction symptoms, and self-administration of emergency epinephrine is not present in children and adolescents even when it sometimes appears so. At-home SCIT, including Curex, is an option for eligible adult maintenance patients, not for pediatric self-injection: children receiving immunotherapy should have every injection given by a trained professional, with a parent or guardian — not the child — responsible for any clinician-approved home arrangement. Families exploring home-based immunotherapy for a child should discuss the options, including sublingual drops as a separate modality, directly with the treating allergist.